4.7 Review

Pre-Eclampsia and Future Cardiovascular Risk Among Women A Review

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 63, Issue 18, Pages 1815-1822

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2014.02.529

Keywords

acute coronary syndrome; angina; coronary artery disease; endothelium; hypertension; myocardial infarction; pre-eclampsia; vascular function

Funding

  1. Medicines Co.
  2. Bristol-Myers Squibb/Sanofi-Avents
  3. Lilly/Daiichi Sankyo
  4. Regado Biosciences
  5. STENTYS
  6. Abbott Vascular
  7. AstraZeneca
  8. Boston Scientific
  9. Covidien
  10. CSL Behring Janssen (JNJ)
  11. Maya Medical
  12. Merck

Ask authors/readers for more resources

Cardiovascular disease continues to be the leading cause of death in the western world. Due to advancements in diagnosis, prevention, and treatment, cardiovascular mortality has fallen in recent years. Previous studies have evaluated the impact of traditional risk factors such as hypercholesterolemia and smoking. However, limited studies have been conducted to evaluate sex discrepancies among patients with cardiovascular disease. Pre-eclampsia is a multisystem placentally mediated disease, which usually arises after 32 weeks of gestation and classically presents with hypertension and proteinuria. Pre-eclampsia affects 2% to 8% of all pregnancies worldwide and is often complicated by fetal growth restriction. Women with a history of pre-eclampsia are at increased risk of future cardiovascular complications. Therefore, this topic is of significance to the cardiovascular health of over 300 million women worldwide. The goal of this review is to determine the association of pre-eclampsia and future cardiovascular risk and to explore the potential management options for these high-risk women. (C) 2014 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available